$349.4 M

TNXP Mkt cap, 07-May-2021
Tonix Pharmaceuticals Net income (FY, 2020)-50.5 M
Tonix Pharmaceuticals EBIT (FY, 2020)-50.5 M
Tonix Pharmaceuticals Cash, 31-Dec-202077.1 M
Tonix Pharmaceuticals EV273.6 M

Tonix Pharmaceuticals Income Statement

Tonix Pharmaceuticals Balance Sheet

Annual

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

747.0205.02.5m1.3m35.7k423.7k68.0k7.4m49.5m43.9m46.2m58.2m48.7m33.0m8.4m14.9m15.6m19.9m34.4m29.3m19.3m16.7m14.7m16.4m12.2m10.0m30.7m55.0m

Prepaid Expenses

64.0k74.5k43.1k67.7k46.4k46.4k554.0k946.0k699.0k1.8m1.6m2.1m3.2m2.4m2.5m1.0m1.1m896.0k1.4m1.4m1.1m2.7m2.0m1.5m2.7m2.6m

Current Assets

2.6m1.4m78.7k491.4k114.4k7.5m50.1m44.8m46.9m60.0m50.3m57.2m30.7m33.7m29.2m23.4m35.5m30.2m20.7m18.2m15.9m19.2m14.2m11.6m33.4m57.6m

PP&E

23.2k53.2k51.0k42.8k38.8k42.8k43.0k71.0k224.0k306.0k316.0k327.0k383.0k349.0k315.0k132.0k118.0k102.0k78.0k65.0k55.0k41.0k36.0k34.0k28.0k37.0k

Total Assets

747.0205.02.6m1.5m190.0k594.5k314.4k7.6m50.2m45.1m47.3m60.5m50.9m57.8m31.3m34.3m29.8m23.8m35.8m30.5m21.0m18.4m16.1m20.0m15.0m12.3m33.9m58.3m

Accounts Payable

182.4k486.9k697.4k870.1k1.5m985.8k1.4m1.5m2.4m2.0m2.8m2.4m2.1m1.9m944.0k841.0k1.2m1.4m1.3m1.6m1.1m1.1m1.0m1.1m1.4m3.2m

Short-term debt

256.0k346.0k

Current Liabilities

284.3k782.8k836.8k1.2m2.3m2.1m2.3m2.4m3.5m3.5m4.6m5.1m3.9m4.2m2.6m1.8m1.8m1.8m2.4m2.5m2.3m2.0m2.0m2.4m2.7m4.7m

Long-term debt

200.0k139.0k51.0k306.0k536.0k

Total Debt

200.0k139.0k51.0k562.0k882.0k

Total Liabilities

13.5k15.2k3.0m810.8k864.3k1.2m2.3m2.1m2.3m2.4m3.6m3.6m4.7m5.2m4.0m4.3m2.7m1.8m1.9m1.9m2.4m2.5m2.3m2.2m2.2m2.4m2.7m4.8m

Common Stock

5.5k34.3k34.3k34.3k2.2k2.2k4.9k10.0k10.0k11.0k16.0k16.0k19.0k19.0k25.0k29.0k4.0k7.0k8.0k8.0k9.0k10.0k6.0k6.0k2.0k49.0k105.0k

Preferred Stock

Additional Paid-in Capital

59.5k59.5k8.0m12.2m12.5m17.2m18.0m28.5m79.8m80.6m89.1m120.9m122.0m141.7m143.7m156.2m160.8m168.3m185.1m185.6m187.9m191.3m194.6m212.5m213.4m218.3m255.6m292.1m

Retained Earnings

(37.9m)(45.4m)(64.0m)(75.8m)(89.0m)(116.4m)(126.2m)(133.8m)(146.3m)(151.1m)(156.9m)(169.3m)(175.4m)(180.9m)(194.7m)(200.5m)(208.4m)(224.3m)(238.5m)

Total Equity

(12.7k)(15.0k)(378.9k)714.9k(674.3k)(639.7k)(2.0m)5.4m47.9m42.7m43.8m56.9m46.2m52.7m27.3m30.0m27.1m22.0m34.0m28.7m18.6m15.8m13.7m17.8m12.8m9.9m31.2m53.6m

Financial Leverage

-0.1 x0 x-7 x2.1 x-0.3 x-0.9 x-0.2 x1.4 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.1 x1.2 x1.2 x1.1 x1.1 x

Tonix Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.5k)(2.3k)(2.0m)(5.1m)(6.8m)(2.0m)(4.1m)(7.2m)(5.2m)(11.2m)(18.6m)(9.7m)(21.4m)(34.7m)(14.0m)(23.8m)(31.4m)(5.1m)(9.8m)(15.6m)(6.9m)(13.0m)(18.5m)(6.2m)(12.1m)(19.9m)(7.3m)(21.5m)

Depreciation and Amortization

2.4k6.1k10.2k4.1k8.1k12.2k4.0k9.0k15.0k22.0k45.0k90.0k57.0k113.0k163.0k24.0k34.0k50.0k15.0k30.0k43.0k9.0k16.0k21.0k6.0k12.0k

Accounts Payable

(512.8k)(208.3k)2.2k44.3k635.4k160.0k635.0k754.0k1.7m502.0k1.3m948.0k(986.0k)(1.1m)(2.1m)(31.0k)307.0k490.0k(32.0k)342.0k(249.0k)(270.0k)(358.0k)(285.0k)(1.7m)118.0k

Cash From Operating Activities

(1.8m)(2.9m)(4.2m)(1.4m)(2.1m)(5.0m)(4.1m)(9.8m)(14.6m)(9.1m)(18.3m)(30.6m)(15.5m)(23.5m)(31.9m)(4.8m)(9.2m)(14.2m)(6.8m)(12.3m)(17.1m)(8.6m)(13.4m)(20.0m)(9.3m)(19.4m)

Purchases of PP&E

(33.8k)(35.7k)(8.1k)(2.0k)(35.0k)(194.0k)(33.0k)(68.0k)(65.0k)(66.0k)(66.0k)(2.0k)(2.0k)(2.0k)(4.0k)(7.0k)(7.0k)(10.0k)(12.0k)(14.0k)

Cash From Investing Activities

(22.0)(33.9k)(35.7k)(22.0)(45.0)(8.2k)(2.0k)(107.0k)(267.0k)(153.0k)(22.2m)4.7m7.5m12.7m4.7m7.2m7.2m(2.0k)(4.0k)(7.0k)(7.0k)(10.0k)(12.0k)(14.0k)

Cash From Financing Activities

4.2m4.2m4.2m405.8k10.6m45.4m45.5m52.9m29.1m29.0m47.7m11.8m15.6m1.1m17.4m17.4m532.0k3.5m6.4m70.0k490.0k5.0m28.8m63.2m

Net Change in Cash

2.5m1.3m(5.5k)(1.4m)(1.7m)5.6m41.3m35.7m38.0m20.0m10.6m(5.2m)(10.7m)(4.2m)(3.5m)1.0m15.4m10.4m(6.2m)(8.8m)(10.8m)(8.6m)(12.9m)(15.0m)19.4m43.8m

Interest Paid

35.2k35.2k35.2k3.2k3.1k3.1k

Tonix Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

-0.1 x